Placebo for BHV-7000 clinical trials

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension

This study is testing a new medicine, BHV-7000, for people aged 18 and over who have a type of epilepsy called idiopathic generalised epilepsy with tonic-clonic seizures. Doctors want to see if the medicine can reduce these seizures and if it's safe to use.